William E Klunk MD
Co-director of the Alzheimer Disease Research Center at UPMC; Professor of Psychiatry and Neurology at the University of Pittsburgh
Join to View Full Profile
3811 Ohara StPittsburgh, PA 15213
Phone+1 412-246-6460
Dr. Klunk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UPMC Medical EducationResidency, Psychiatry, 1984 - 1988
Washington University in St. Louis School of MedicineClass of 1984
Certifications & Licensure
PA State Medical License 1985 - 2021
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 1 citationsImpact of the polygenic risk scores for attention-deficit/hyperactivity disorder in Alzheimer's disease.Douglas T Leffa, Guilherme Povala, Bruna Bellaver, João Pedro Ferrari-Souza, Pamela C L Ferreira
Alzheimer's & Dementia. 2025-02-01 - 9 citationsMulti-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease.Xuemei Zeng, Tara K Lafferty, Anuradha Sehrawat, Yijun Chen, Pamela C L Ferreira
Molecular Neurodegeneration. 2024-10-10 - 3 citationsEffect of blood collection tube containing protease inhibitors on the pre-analytical stability of Alzheimer's disease plasma biomarkers.Yijun Chen, Xuemei Zeng, Jihui L Diaz, Anuradha Sehrawat, Tara K Lafferty
Journal of Neurochemistry. 2024-09-01
Journal Articles
- Genome-Wide Association Study of Brain Amyloid Deposition as Measured by Pittsburgh Compound-B (PiB)-PET ImagingOscar L Lopez, Andrew J Saykin, Howard J Aizenstein, William E Klunk, Beth E Snitz, Nature
Press Mentions
Scientists Validate New Lab Test Platform for Alzheimer’s Blood BiomarkersOctober 10th, 2024
Pitt Scientists Validate New Lab Test Platform for Blood Biomarkers of Alzheimer's DiseaseOctober 9th, 2024- Double Whammy: APP Uppsala Deletion Ups Aβ and Its Aggregation PropensityAugust 24th, 2021
- Join now to see all
Grant Support
- Natural History Of Amyloid Deposition Familial ADNational Institute On Aging2010–2012
- Amyloid Pathology And Cognition In Normal ElderlyNational Institute On Aging2005–2012
- In Vivo PIB PET Amyloid IMAGING: Normals, MCI &DementiaNational Institute On Aging2010–2011
- Amyloid-Lowering Small Molecule Ab-Binding Agents In ADNational Institute On Aging2006–2010
- In Vivopib PET Amyloid IMAGING: Normals, MCI &DementiaNational Institute On Aging2008–2009
- Natural History Of Amyloid Deposition In Familial Alzheimers DiseaseNational Institute On Aging2007–2009
- Cross-Sectional Assessment Of In Vivo Amyloid In MCI And ADNational Institute On Aging2005–2009
- Natural History Of Amyloid Deposition In Familial ADNational Institute On Aging2005–2006
- PET Tracers To Monitor Vaccine And Immune Therapy For ADNational Institute On Aging2001–2005
- PET Imaging Probes For Amyloid In Alzheimers And AgingNational Institute On Aging2001–2005
- Clinical Metabolic Correlation In Dementia By Proton NMRNational Institute Of Mental Health1995–1999
- Chemical And Physical Studies Of Beta Amyloid ProteinNational Institute On Aging1996–1997
- NMR Studies Of Brain Aging In Alzheimer'S DiseaseNational Institute On Aging1990
- Molecular Probes For Alzheimer Beta-Amyloid ProteinNational Institute On Aging1988–1989
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
